Valuation: Ocular Therapeutix, Inc.

Market Cap 1.45B 1.3B 1.19B 1.08B 2.04B 136B 2.11B 14.31B 5.71B 72.65B 5.44B 5.32B 229B P/E 2026 *
-4.42x
P/E 2027 * -4.67x
Enterprise Value 1.02B 918M 839M 766M 1.44B 96.19B 1.49B 10.11B 4.03B 51.32B 3.84B 3.76B 162B EV / Sales 2026 *
19.4x
EV / Sales 2027 * 12x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day+2.57%
1 week-5.38%
Current month-5.38%
1 month-8.78%
3 months-28.24%
6 months-31.87%
Current year-45.68%
1 week 6.41
Extreme 6.41
7.24
1 month 6
Extreme 6
7.75
Current year 6
Extreme 6
13.03
1 year 6
Extreme 6
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
08/10/26 Sell

General Counsel

-11,984 0.0057%
02/10/26 Sell

Executive/Senior Manager

-9,990 0.0047%
02/10/26 Sell

Chief Technology Officer

-10,869 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%-5.38%-39.22%+132.22% 1.45B
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.18%-1.92%+32.64%+82.32% 418.12B
Weighted average by Cap. -0.04%-1.96%+42.68%+88.13%

Financials

2026 *2027 *
Net sales 52.84M 47.39M 43.31M 39.53M 74.49M 4.97B 76.83M 522M 208M 2.65B 198M 194M 8.37B 102M 91.52M 83.64M 76.35M 144M 9.59B 148M 1.01B 402M 5.12B 383M 375M 16.16B
Net income -334M -300M -274M -250M -471M -31.42B -486M -3.3B -1.32B -16.76B -1.25B -1.23B -52.92B -330M -296M -271M -247M -466M -31.06B -480M -3.26B -1.3B -16.57B -1.24B -1.21B -52.31B
Net Debt -425M -381M -348M -318M -599M -39.96B -618M -4.2B -1.67B -21.32B -1.6B -1.56B -67.31B -225M -202M -184M -168M -317M -21.13B -327M -2.22B -885M -11.27B -844M -825M -35.59B
Projected Income Statement - Annual - Ocular Therapeutix, Inc.
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
06/11/26 $6.595 +2.57% 1,957,239
05/11/26 $6.430 -9.94% 3,130,015
04/11/26 $7.140 +4.69% 3,360,664
03/11/26 $6.820 +1.34% 2,001,472
02/11/26 $6.730 -3.44% 1,883,301
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ocular Therapeutix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.595USD
Average target price
25.45USD
Spread / Average Target
+285.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ocular Therapeutix, Inc.
  1. Stock Market
  2. Stocks
  3. OCUL Stock